Castle Biosciences (CSTL) Receivables (2018 - 2026)

Castle Biosciences has disclosed Receivables across 9 years of filings, most recently posting $48.3 million for Q2 2026.

• In Q2 2026, Receivables fell 7.59% year-over-year to $48.3 million; the TTM figure through Jun 2026 stood at $48.3 million (down 7.59% YoY), while the FY2025 annual figure was $43.4 million, down 15.3% from the prior year.
• Receivables came in at $48.3 million for Q2 2026 at Castle Biosciences, up from $42.3 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $56.4 million in Q1 2025 to a low of $19.9 million in Q1 2022.
• Average Receivables over 5 years is $39.2 million, with a median of $42.5 million recorded in 2024.
• Year-over-year, Receivables surged 63.15% in 2023 and decreased 25.0% in 2026.
• Over 5 years, Receivables stood at $23.5 million in 2022, then jumped by 63.15% to $38.3 million in 2023, then jumped by 33.72% to $51.2 million in 2024, then slipped by 15.3% to $43.4 million in 2025, then advanced by 11.43% to $48.3 million in 2026.
• Per Business Quant data, the three most recent Receivables figures were $48.3 million in Q2 2026, $42.3 million in Q1 2026, and $43.4 million in Q4 2025.